19
Participants
Start Date
June 15, 2012
Primary Completion Date
September 30, 2015
Study Completion Date
December 20, 2017
Selumetinib
"The treatment schedule requires selumetinib to be taken either once daily at the same time each day or twice daily approximately 12 hours apart. Selumetinib should be taken with water at least 2 hours after a meal and 1 hour before the next meal. Selumetinib capsules will be administered in a continuous 21 day cycle (6 cycles), unless disease progression occurs.~For phase I there were 4 potential dosing levels:~Level -1 - 50mg once daily (od) (50mg daily total)~Level 1 (starting dose level for phase I) - 50mg bi-daily (bd) (100mg daily total)~Level 2 - 75mg bd (150mg daily total)~Level 3 - 100mg bd (200mg daily total)~Phase I has been completed and identified 75mg bd as the recommended phase II dose.~Phase II has begun and is utilising a dose of 75mg bd of selumetinib."
Brighton and Sussex University Hospitals, Brighton
Beatson West of Scotland Cancer Centre, Glasgow
Royal Free Hospital, London
Chelsea & Westminster Hospital, London
The Christie Hospital, Manchester
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield
Collaborators (2)
University of Birmingham
OTHER
AstraZeneca
INDUSTRY
Thermo Fisher Scientific, Inc
INDUSTRY
Cancer Research UK
OTHER
University of Sheffield
OTHER
Sheffield Teaching Hospitals NHS Foundation Trust
OTHER